Pliant Therapeutics Q3 loss $30.6M; positive Phase 2a IPF data; $215M offering closed

PLIANT THERAPEUTICS, INC.

2022-Q3 EPS reported -$2.22 revenue$7,720,000

Net loss of $30.6M in Q3 2022 vs $27.0M prior year; cash & investments $360.2M, funding to mid-2025.
Positive Phase 2a data for bexotegrast in IPF: dose-dependent improvement in FVC, QLF, and biomarkers over 12 weeks.
Closed public offering yielding $215.4M net proceeds to fund clinical programs and operations.
Appointed Dr. Katharine Knobil to Board; oncology IND submission expected by end of 2022.
DSMB reviews for INTEGRIS-IPF and INTEGRIS-PSC trials recommended continuation without modification.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLIANT THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001746473-22-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.